Brokerages expect Horizon Pharma PLC (NASDAQ:HZNP) to report sales of $254.14 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Horizon Pharma PLC’s earnings, with estimates ranging from $249.55 million to $258.72 million. Horizon Pharma PLC posted sales of $208.70 million in the same quarter last year, which suggests a positive year-over-year growth rate of 21.8%. The firm is scheduled to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Horizon Pharma PLC will report full-year sales of $254.14 million for the current year, with estimates ranging from $1.02 billion to $1.07 billion. For the next financial year, analysts forecast that the company will report sales of $1.08 billion per share, with estimates ranging from $1.05 billion to $1.10 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Horizon Pharma PLC.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the prior year, the firm posted $0.56 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis.

HZNP has been the topic of a number of research analyst reports. BMO Capital Markets reissued a “buy” rating and issued a $17.00 price target (down from $24.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Mizuho lowered Horizon Pharma PLC from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $22.00 to $10.00 in a research note on Tuesday, May 9th. Cowen and Company set a $20.00 price target on Horizon Pharma PLC and gave the stock an “outperform” rating in a research note on Tuesday, May 9th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price target (down from $35.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Finally, Jefferies Group LLC set a $14.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $19.69.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/31/horizon-pharma-plc-hznp-expected-to-announce-quarterly-sales-of-254-14-million.html.

Several large investors have recently made changes to their positions in the stock. Icon Advisers Inc. Co. increased its stake in shares of Horizon Pharma PLC by 299.4% in the first quarter. Icon Advisers Inc. Co. now owns 62,300 shares of the biopharmaceutical company’s stock valued at $921,000 after buying an additional 46,700 shares during the last quarter. Swiss National Bank increased its stake in shares of Horizon Pharma PLC by 1.6% in the first quarter. Swiss National Bank now owns 239,056 shares of the biopharmaceutical company’s stock valued at $3,533,000 after buying an additional 3,700 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Horizon Pharma PLC by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 764,571 shares of the biopharmaceutical company’s stock valued at $11,300,000 after buying an additional 22,918 shares during the last quarter. US Bancorp DE increased its stake in shares of Horizon Pharma PLC by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 368 shares during the last quarter. Finally, Capital Fund Management S.A. increased its stake in shares of Horizon Pharma PLC by 180.2% in the first quarter. Capital Fund Management S.A. now owns 818,015 shares of the biopharmaceutical company’s stock valued at $12,090,000 after buying an additional 526,076 shares during the last quarter. Institutional investors and hedge funds own 82.30% of the company’s stock.

Shares of Horizon Pharma PLC (HZNP) traded up 2.86% during midday trading on Thursday, hitting $13.68. 985,879 shares of the stock traded hands. The company’s 50 day moving average price is $12.66 and its 200-day moving average price is $13.40. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98. The stock’s market cap is $2.23 billion.

Horizon Pharma PLC announced that its Board of Directors has approved a stock repurchase plan on Monday, May 8th that authorizes the company to buyback 1,000% of outstanding shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma PLC (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.